Moderna's stock soared to an all-time high of $497.49 back in August 2021, driven by increased demand for its COVID-19 vaccines. However, since then, the stock has continued to erode investors ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna (MRNA-1.32%), a leader in the field of messenger RNA (mRNA)-based vaccines and therapeutics, is a prime example. The company's stock price skyrocketed in 2021, thanks to the strong sales ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

The bigger story for Moderna, however, is that it should soon expand beyond COVID-19. The U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 12, 2024, for its approval decision on ...

Moderna stock (NASDAQ: MRNA) has rallied from around $104 per share at the end of 2020, to about $485 as of Monday, an increase of over 4.5x. This compares to the S&P 500 which is up by just about ...

Moderna stock declined by about 30% over the last week (five trading days) following the company’s weaker than expected Q3 2021 results. While Moderna’s revenue for Q3 grew by almost 13% ...